{"name":"Intensity Therapeutics, Inc.","slug":"intensity-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"INT230-6","genericName":"INT230-6","slug":"int230-6","indication":"Melanoma (intratumoral injection)","status":"phase_3"}]}],"pipeline":[{"name":"INT230-6","genericName":"INT230-6","slug":"int230-6","phase":"phase_3","mechanism":"INT230-6 is a dual-acting immunotherapy that combines a TLR9 agonist with doxorubicin to activate innate immunity and promote anti-tumor immune responses.","indications":["Melanoma (intratumoral injection)","Head and neck squamous cell carcinoma (intratumoral injection)","Merkel cell carcinoma (intratumoral injection)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNc3FPXzZkemFhQTQ0QXFKUUVtSXpkVnRkdmQ4ZXRETlVkdkZwRlRjZVdjamJreW8wbVA0Y0kwQXZQQ3M0UHBGb3BlZ2c4VE1DU2IxYUhqTDF6c090OVdrTDlDRmxMME5JbTZCaDRaQnIwVmpHWEJrQk5JNlNVZXA3YTNBa0ROMWh4VWNxQTQzemhCcXQwRXFVT2ZxZml0MlVNcjhhZ1RYYnhkMkpKMVU1N2hnRQ?oc=5","date":"2026-03-27","type":"pipeline","source":"Stock Titan","summary":"[10-K] INTENSITY THERAPEUTICS, INC. Files Annual Report - Stock Titan","headline":"[10-K] INTENSITY THERAPEUTICS, INC. Files Annual Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOWS1aNUhfWUNZLXR2V3g0Wmg3aG91TnkzLTNxR0l3ZDJRTkljR1ZOa2dtbHZCRUwzQ2JZVnlFekc0T1JMR0pOV2lZZC1KNFVhLTVmZV9sOW9KQXFwaUFEV3hIMTFnS3Jvc3BLOUp2RU1XMjhCS3ltal9iVU80MXp0Tnh3NkoyQzVWV0tQb0dtVG5VSkFvN1ZNbXlMWEhMQ1BKRGY4VDlPb3A4NGs1X1dLVmRjQTVlbU0?oc=5","date":"2026-03-24","type":"patent","source":"finviz.com","summary":"Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US - finviz.com","headline":"Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxNUXNJb1NydEdIU3ZRTG1rQkVXX1RJMG9vNkhpMjhsX1pjd1pkZTVhVzlqejNLcXlfZEl6UlZ2SXhoZ3FURjJpOHdYUUxnRDZmemtJdENMLTNBVnVfYkRVdzQyVmRjSTBLWDZHR2dfcHQyUU1KQVItVUpWbk5ZZmt5UjN4ck1ZRVNMeG9LeEx4UXpra3JKc0lPT01FMkJ1SXhCdDYzb2RCZ0xmaTNWMUJYWDhJRXA1TVNrZk9VRnZuRmhSSWozTWlUQXI1ck1nVWFkaDBuWHQ1YWdtRFBvRndtNEFTRjcyRkd1YUFlYW5aalpCOGVPcEtfb2JoSTd4MlB4SGh6Xw?oc=5","date":"2026-03-12","type":"trial","source":"PR Newswire","summary":"Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study - PR Newswire","headline":"Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOV3Zhdk50SWxWVlYxYkNOcUhrSXAtcDJ2SXNjOWl4ckxKZ0ZUbFlTRWNpamNNZi13aEJnbGZGRk5XbU5RNVNldl9xN09jdl95Qnl5Z2pTMEI3TnNZQ01BUkRUUXpKcTFXQXlqcXJYQzVwa1h1MXVwMWZsZEYwUWM1elBTV3JmaGFlUG0xY214SHozLUU5NWpma1V3anFic0hfTl9OUG1sdmN0RXdQZ0JnbzFLTmlrVXhVZENWZDlrMGdrR25vLXNrOFJJTy04NXdhWUItWHdpcw?oc=5","date":"2026-03-06","type":"pipeline","source":"PR Newswire","summary":"Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement - PR Newswire","headline":"Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxNbVpHSEo0WGlCQ2lMdzBhN2FkSjQwaXFMOVVDRUJOUFZXOXhfdFh0NTkwM2NpcHd4Y2ppcHhoS3dkelhXSmRaZzk0WjBoSzZwbnpGRzVCbU44ZDhwd3lSdzQ5WDA2TGdJUTd0endNTmFiRzFYcnhIUy1mcWt2Z2NoR09uSDM0U2gxUjZYQWVONnBvQ0VkeTdjbmR3eDBYNDA5dUdzWWxrTVMtU2NNOU5qOGtzaFNrcVJNbGVkWVlmRElwdjB5QVUwMVZTeUwyZ0Y3WkxkcTJveUJ2dHdW?oc=5","date":"2026-01-13","type":"pipeline","source":"PR Newswire","summary":"Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities - PR Newswire","headline":"Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQZ2N3Q0xWWk9jdkhMR2JYZDFCVVlxa2YtUXpFTHRTWTRWbHU3ZWtRZ1hNLW1MRldxTzlneFh6Y2VhcENyZjNHdVFkc3JIY0djQmpXU3Z4TUNjbWFtbzZvTWd0Zm1aWmNOenJqMzdnSEpkVE9mYS05MFdFUWdfcGNPeWJrdy16bVk4TjJGS2RhMjNsbXg0TEJhUFRUOWJjYzJ0Z0o5SHJjVnNyUy16U21KWjlVWlh4U0F4VURIendpLXFKT0tBZ0lPUi1fcWEyUFNhTjB3MGZNUTR4NlcwMmwtWkxlM3ZlbVkz?oc=5","date":"2025-12-11","type":"pipeline","source":"PR Newswire","summary":"Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium - PR Newswire","headline":"Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxPZjJqU19vaWs4U2VLMzlvUFVVWW9qUzUybDY1bmQ4Sk1KR3pFT0dlS2RFZk85dWtkYnJhckZ5TFZvVnMwOXRzZTRJQ05RVUNXUlNiS1ZFLTNWY2h6S1VSeXBIaU41X0Jsc0xGWjZuVElzUnNLRUhqcG5OcWdWY0RWU3FFbER1RnBDWjBZNjNRNUR6dmFWQUhHdmd4VVotazZDNElqNWZYS096Q2NUVGNCNFFOejRITVM1elQ2c2R4LWY0UWNiUUk1TUlFRnFqTW42bGhBaDBacFlKWVRqWEY4WHgxN1IzMUg3a1lOQU1naERaWXFuNGc?oc=5","date":"2025-12-04","type":"pipeline","source":"PR Newswire","summary":"Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium - PR Newswire","headline":"Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxNZXFpbmx2WGhSRGU4b2pRNllEeVhMbHdEUjRBcVVUQjJaSjRCUHhveURTVU5DcWNPcm1aQXg5LTlDSHhRbmg1Z3hWSElaeDhyc1ZtQ05JcElNZ0poeU95QVlKNEtrbW0yaTVQeWFHNGJvT0Ztb3JDTzBobmRnRWxZUmdHMGM0WktlbHZiR3V1NVljaTZaaHlxZlc4emFIOERYaDN2QlJmWkx4OFJIdEtyVFE5VUtCbVo0bU1BRFQ4VzZFUEVFNTlBRmF0RFZtWmpBeG0tbVZ4Y1VHcnhjOVh3NnJBZ2xZd3Nt?oc=5","date":"2025-11-06","type":"earnings","source":"PR Newswire","summary":"Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire","headline":"Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxPTmtwTW1JRVk0cUdkY1dzaXVnQUl0a0t6LXp3UWZFZzJaVmlJdkNibVY1QjZWNGRsdzRrbzRKelI3Vzh6c09KejNlTzRXNERLeE9jQ21OTDA4bmcwdjNzZFVlSFZGX1hUeTFjLXdKX3JtRTNKZWJuVkNweEpPY3dJbkhjVGtDUlE3Y05XbGxQcF80RUhUX045ck95NWFGSmpSRlVDdjFfV0NwVmNIVGtVVFFnbHNQaDBWQmZ4MnlXSmMzb2prbGx5dWs0S2dySGZDUDRidWdCSTlxRW91RU5LRGVvaTZ2TGR5akhmRQ?oc=5","date":"2025-10-31","type":"pipeline","source":"PR Newswire","summary":"Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock - PR Newswire","headline":"Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gJBVV95cUxNX2l1SzF6eFRHZk5IdTZvU2MxdTd6Mk95U0tWSVcwTHlrTjFyRU1PLU10OXFHR0Vrbk5TcWQxeG12a24zbU1paW5pa3dvSGUwazhqSnlQVVBxQ3B0cmtjMlI5d3hNQnRiakRlZFd2OFo0YUNlakEwZE83U0RqTi1NYzB4czI5N1BYWDRUV1BKTUhQTjJKLW5rU3RRX192bVNhS3pkUVQtSk9lX3BvS1A0cmlDcGlTSjc3NzdxWGtsd095al9qN0Rmei1Fa0FZaEVZTG9VOFZfcVo4U19GVWY2ODgyYU95VEdEc015WE95cnpiUi00aFFsZmlMUXVIWkRFZG5Ob19oVmV0NnpneHlyS0t1MWtuampBcExMZmZjVUszeUNoQklkcHpwWlMyaUdlN1E2dWI3SUxleFFLWVMzNUFCdjdsVnJSMkFHS0hfSlJGNDRaWWhFeXczWl9HZw?oc=5","date":"2025-10-30","type":"pipeline","source":"PR Newswire","summary":"Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal - PR Newswi","headline":"Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Re","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNbDNoSHFVVWJoUEMzNlc1TlBTTWFiZEpqLW96STZUUEV4YXlXZGwwTGJ6NHVUZ0xGMTlPWXgxNms5aWplUDQteVpSYWZfdmN3RzY0VUpWVXNOZ2NHYWdJbVpmNWhHT1JCcVA5VUwxYjFMQUFfa1lhMVllTFJMS1UxSEdRNUVVUVRhbkxtWGh5TjY1YkF0YnF6RTVmUlhrTTlkcjlxMndPZkQzaDRyUjJOZ0NfLUdOZGpVR05fNnBvVmV3d1pFdXZ3NHRjSGZreHV5YXVUTXdBV1BjZ24xU3ZyQmxPN19TWVVqd2c?oc=5","date":"2025-09-10","type":"trial","source":"PR Newswire","summary":"Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update - PR Newswire","headline":"Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPX1JxYno0Vm5YbUlOMzREQ1BBT1VSa0UwV2M5Vk1QR3NLQ19jR2lZVW52OVlibFBzU3NSTVBseUVxcU9pUUhOSjZKNmlzVEJqdUFlZmZ4bGlWVmJ3S3QtRExmdnc5LUJEaDJoUndQc0JwbU1VZENqWGpneVlqaGdJZnpBVjNmd2tFN016ZG5URXpQLWtYcUE5ckl6MURzOGV0REI5Z05DdWp6bldjUEtpWl84eC12cmxmMExpQjdMeHBfN01mZHFIcjQ2LWZSMmxLVDNJRGRzeXRoRldralRWQUhJenEyREFsWWc?oc=5","date":"2025-08-07","type":"earnings","source":"PR Newswire","summary":"Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire","headline":"Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}